Vista Pharma. (524711)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹14.83, Vista Pharma is the kind of stock I would circle and then walk past. Graham taught me to buy businesses with a margin of safety, but here the market is paying ₹14.83 for book value of ₹8.12, for a company that is losing money. The P/E is meaningless because earnings are negative; latest quarter sales are just ₹2 Cr with a net loss of ₹2 Cr. ROE is -15.95%, ROCE -8.53%. Every rupee of retained equity is earning negative returns. Sales are shrinking 5.47% and profit growth has collapsed 75.76%. This is not a business; it is a cash incinerator with a pharma label. The Piotroski F-Score of 2/9 reinforces the picture of weak financial health. There is no dividend to compensate while I wait. The stock has run from ₹5.71 to ₹14.83, near its 52-week high, which tells me sentiment is hot, not that fundamentals have improved. I cannot calculate a fair value from negative earnings, and I refuse to speculate on a story where promoter holding and debt/equity are unavailable. If this is a turnaround, I need evidence of change: positive operating cash flow, rising margins, and a credible plan. Buffett says 'be fearful when others are greedy' - at 1.83 times book for a loss-making pharma, the greed is on display. The only sound decision for a value investor is to wait, watch, and let Mr. Market offer a realistic price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer